Table GPSurvey-1. Lifetime prevalence of drug use among all adults (15-64 years old) in nationwide surveys among the general population. Part (i) Lifetime prevalence all adults (percentage)

	Country and geographical area	Ref.	Year	Sample size	Cannabis	Cocaine (a)	Amphet-amines (b)	Ecstasy (c)	Hallucino-gens	LSD

	Belgium
	Vlanderen (Brussels excluded)	⁽¹⁾	1994	2259	5.8	0.5	0.9	0.5
	French Community	⁽²⁾	1996-97	976	12.8
	French Community	⁽³⁾	1998-99	1108	20.8
	French Community	⁽⁴⁾	2000	694	22.2
	National coverage (Flemish, Wallon and Brussels region)	⁽⁵⁾	2001	7347	10.6		2.1
	Czech Republic
	National	⁽¹⁾	2002	2526	21.1		2.3	4.0		2.2
	Denmark
	National	⁽¹⁾	1990	2000	22.0	1.0	3.0
	National	⁽²⁾	1994
	National	⁽³⁾	2000	11825	31.3	2.5	5.9	1.0	3.1	1.4
	Germany
	Western Germany	⁽¹⁾	1990
	East Germany	⁽²⁾	1990
	Old Länder (W. Germany) and New Länder (E. Germany)	⁽³⁾	1995	7833	11.9	1.9	2.4	1.4	1.7
	Old Länder (W. Germany) and New Länder (E. Germany)	⁽⁴⁾	1997	8019	11.5	1.4	1.5	1.5	1.3
	National	⁽⁵⁾	2000	8139	19.3	2.3	2.3	1.6	2.7	1.8
	Estonia
	National	⁽¹⁾	1998	2317	5.0	1.0	1.0	1.0
	Greece
	Athens	⁽¹⁾	1993	2103	9.4	0.8	1.0
	Greece except Aegean and Ionian Islands	⁽²⁾	1998	3398	13.1	1.3	0.6	0.3	1.0
	Spain
	National	⁽¹⁾	1995	8888	14.2	3.7	2.5	2.0
	National	⁽²⁾	1997	12515	21.7	3.2	2.6	2.5	2.7
	National	⁽³⁾	1999	12234	19.8	3.2	2.2	2.4	1.9
	National	⁽⁴⁾	2001	14113	24.5	4.9	3.0	4.2	2.9
	France
	National	⁽¹⁾	1992	2099	11.3	0.7
	Metropolitan France	⁽²⁾	1995	1787	16.0	1.2	0.7		1.7
	National	⁽³⁾	1999	1742	21.9	1.5	0.2	0.9	1.7	1.2
	National	⁽⁴⁾	2000	11317	22.5	1.6	1.5	0.9		1.7
	Metropolitan France	⁽⁵⁾	2002	1745	26.2	2.2	0.4	0.9	2.1	1.2
	Ireland
	National	⁽¹⁾	1998	na	19.9
	National	⁽²⁾	1998	826	14.3
	National	⁽³⁾	2000	907	11.3
	National	⁽⁴⁾	2002-03	4925	17.6	3.1	3.0	3.8		3.0
	Italy
	National	⁽¹⁾	2001	6032	21.9	3.4	1.5	1.8	1.5	0.0
	Latvia
	National	⁽¹⁾	2003		10.6	1.2	2.6	2.4	1.5	1.1
	Luxembourg
	National ( representative regional communities)	⁽¹⁾	1998	na	12.9	0.2		1.2	3.4	1.4
	Hungary
	National	⁽¹⁾	2001	2359	5.7	0.8	1.6	2.0	1.6	1.6
	Netherlands
	National	⁽¹⁾	1997-98	17590	19.1	2.6	2.2	2.3	3.3	1.5
	National	⁽²⁾	2000-01	14045	21.0	3.6	3.1	3.6	3.8	1.3
	Poland
	National	⁽¹⁾	2002		7.7	0.8	1.9	0.7	0.8	1.2
	Portugal
	National	⁽¹⁾	2001	14184	7.6	0.9	0.5	0.7		0.4
	Slovakia
	National	⁽¹⁾	2002	1405	14.9	1.0	0.8	1.8	0.6
	Finland
	National	⁽¹⁾	1992	3457	4.8		0.2
	National	⁽²⁾	1996	3009	7.3		0.7
	National	⁽³⁾	1998	2568	10.3	0.7	1.1	0.5
	National	⁽⁴⁾	2000	1677	9.9	0.6	1.0	0.6		0.4
	National	⁽⁵⁾	2002	2377	12.8	0.7	2.2	1.4		0.8
	Sweden
	National	⁽¹⁾	1994	806	7.1	0.4	1.4	0.0		0.4
	National	⁽²⁾	1996	1136	9.8	1.0	2.1	0.3		0.2
	National	⁽³⁾	1998	1359	13.9	0.6	2.0	0.3
	National	⁽⁴⁾	2000	1750	12.5	0.7	1.9	0.2		0.3
	United Kingdom
	England and Wales	⁽¹⁾	1994	9645	21.0	2.4	8.2	2.4	7.3	4.4
	England and Wales	⁽²⁾	1996	10935	23.5	3.1	9.3	3.8	7.8	5.4
	England and Wales	⁽³⁾	1998	9984	26.8	3.8	10.8	4.2	8.4	5.6
	England and Wales	⁽⁴⁾	2000	13018	29.5	5.6	12.3	5.3	9.3	6.2
	England and Wales	⁽⁵⁾	2001-02	20165	28.9	5.2	11.6	5.9	8.2	5.4
	England and Wales	⁽⁶⁾	2002-03	23586	30.6	6.2	12.3	6.6	9.2	5.9
	Northern Ireland	⁽⁷⁾	2002-03	3517	16.8	1.7	3.9	5.9	6.5	4.5
	Norway
	National	⁽¹⁾	1999	1803	10.6	1.2	2.6	2.4	1.5	1.1


Notes:
(a) Cocaine any form.
(b) For Belgium National 2001 and for Metropolitan France 1995: amphetamine+ecstasy.
(c) For Spain: ecstasy and other designer drugs.
This table aims to present national surveys. Exceptionally some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates, which are not comparable with estimates for whole countries (or big regions with urban and rural areas). Athens was included as reference point for 1993 survey.
In surveys with small sample sizes results should be interpreted with caution.
Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15-64, young adults: 15-34). In countries where age ranges are more restrictive prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups.
For methods and definitions see [Methods and definitions - Prevalence and patterns of drug use in the general population].
For survey methods see [Table GPSurvey-1 Part (ii) Survey methods].
Sources: see [Table GPSurvey-1 Part(iii) Sources].

Download